Glenmark Pharmaceuticals Limited — Board Meeting, 14-08-2025: Outcome of Board Meeting

Glenmark Pharmaceuticals' board has approved the financial results for the quarter ended June 30, 2025. The company reported consolidated revenue from operations of Rs. 3,264.44 Cr. Consolidated profit after tax attributable to owners stood at Rs. 46.87 Cr, leading to an EPS of Rs. 1.66. These results include an exceptional charge of Rs. 323.23 Cr for a US antitrust lawsuit settlement, reflecting the company's agreement to resolve allegations while denying liability.